Breast cancer targeted therapy and pro/anticarcinogenic effect modulation of environmental chemical agents


The project focuses on a better understanding of the fact that risk factors may be associated with changes in epigenetic alterations, especially DNA methylation, and these changes may be associated with other alterations at the genomic level (mRNA and miRNA) or proteomics. We intend to develop and validate a new therapeutic model, which is based on evaluating the effect of a chemical compound on several normal and tumour breast cancer cell lines. In order to be able to identify the key dose that turned a carcinogenic compound into a therapeutic compound, other therapeutic agents such as p53siRNA and EGCG will be associated.

Starting / Ending Date

01/07/2014 – 30/09/2017

Project Coordinator

University of Medicine and Pharmacy “Iuliu Hațieganu” Cluj-Napoca – Romania


Funder: Executive Unit for financing education Higher, research Development and innovation (UEFISCDI)
Grant Number: PN-II-PT-PCCA-2013-4-0030
Total Amount: 1.250.000 RON

Staff from Department of Public Health

Project Partners

University of Medicine and Pharmacy “Iuliu Hațieganu” Cluj-Napoca

Environmental Health Center Cluj-Napoca

Oncology Institute “Prof. Dr. Ion Chiricuta” Cluj-Napoca